Skip to content
Open access

Adaptive bridging and holding therapy frequently reduces tumor burden and is associated with reduced toxicity after CAR-T cell therapy in multiple myeloma: A single-center real-world experience.

Aug 2026 · Transplantation and Cellular Therapy · 0 citations · 47 references
Medicine

TL;DR

Deeper pre-infusion response was associated with significantly lower toxicity after BCMA-directed CAR-T therapy, identifying pre-infusion disease control as a potentially modifiable determinant of toxicity.

Abstract

Background

Chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA) has transformed the treatment of relapsed/refractory multiple myeloma (RRMM) but is associated with substantial toxicity. The association between pre-infusion disease control and post-infusion toxicity remains underexplored, and no treatment standards exist for bridging therapy in RRMM.

Objective

To characterize the holding and bridging regimens used in clinical practice, evaluate their effectiveness in achieving pre-infusion disease response, and assess the association between the depth of pre-infusion response and the incidence of post-infusion toxicity. STUDY

Design

In this single-center retrospective analysis, 88 consecutive RRMM patients received idecabtagene vicleucel (n=22) or ciltacabtagene autoleucel (n=66). Pre-infusion response was assessed using International Myeloma Working Group criteria. The primary endpoint was a composite of any ≥Grade 2 toxicity across six categories: cytokine release syndrome, immune effector cell associated neurotoxicity syndrome, immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome, early and late immune effector cell-associated hematotoxicity, and infection, evaluated using log-link regression to estimate risk ratios (RR).

Results

Among the 88 patients included in the analysis, the median number of prior lines of therapy was 4. Holding and bridging therapy were administered in 80 (90.9%) and 87 (98.9%) patients, respectively. Twenty-four different therapeutic regimens were administered. Among the 79 patients who received both holding and bridging therapy, 32 (40.5%) changed regimens after apheresis due to insufficient response. Overall, 60/88 patients (68.2%) achieved ≥ partial response before infusion. Patients achieving ≥ very good partial response (VGPR) had a composite ≥Grade 2 toxicity rate of 8/35 (22.9%) compared with 25/53 (47.2%) in those with <VGPR (RR 0.48, 95% CI 0.25-0.95; p=0.035); this association persisted in the adjusted model including all 88 patients (adjusted RR 0.50, 95% CI 0.26-0.98; p=0.042). One case of CAR-T induced Guillain-Barré syndrome and seven cranial nerve palsies were observed, no parkinsonism occurred. Non-relapse mortality was 2/88 (2.3%). Alkylator-based holding therapy did not lead to an increased number of out-of-specification product.

Conclusion

Deeper pre-infusion response was associated with significantly lower toxicity after BCMA-directed CAR-T therapy, identifying pre-infusion disease control as a potentially modifiable determinant of toxicity. Intensified holding and bridging strategies were feasible and effective in reducing disease burden in highly pretreated patients, supporting prospective validation of response-adapted bridging to improve the safety of CAR-T therapy in RRMM.

Read PDF

Similar papers

Open access Sep 2026

Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma.

Disease burden at the time of BCMA-directed chimeric antigen receptor (CAR) T-cell infusion is a key determinant of outcome in relapsed or refractory multiple myeloma (RRMM). Bridging therapy is frequently administered between leukapheresis and infusion to prevent disease progression, yet its clinical impact remains un...

M. Wesener, U. Demel, T. Pabst et al. · 0 citations
Review Open access Sep 2026

Beyond Remission: Risk-Adapted Maintenance and Mechanism-Guided Salvage After CAR T-Cell Therapy for Multiple Myeloma.

BACKGROUND B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy can induce deep responses in relapsed or refractory multiple myeloma, yet relapse remains frequent. Neither post-infusion maintenance nor salvage after CAR T-cell failure has an established standard. MAIN TEXT This rev...

Shuai-Xi Su, Si-Jia Yan, Jia-Ying Wu et al. · 0 citations
Open access Sep 2026

Sequencing BCMA-Directed Therapies in Relapsed/Refractory Multiple Myeloma: A Real-World Comparison of CAR T-Cell Therapy and Bispecific Antibodies

Simple Summary B-cell maturation antigen (BCMA)-directed therapies (BDT) are approved for the treatment of relapsed/refractory multiple myeloma (RRMM). Several treatment modalities exist including chimeric antigen receptor T-cell therapy (CAR-T), bispecific antibodies (BsAbs), and antibody-drug conjugates (ADC). The ef...

Osama M. Younis, Sencer Goklemez, Carmel Awadallah et al. · 0 citations
Open access Aug 2026

BRIDGE-2M: Optimizing Bridging Therapy Prior to CAR-T Therapy in Multiple Myeloma: A Modified Double-Blind Delphi Panel of US Physicians.

INTRODUCTION We aimed to achieve consensus on optimal bridging therapy (BT) selection for patients with relapsed/refractory multiple myeloma (RRMM) undergoing chimeric antigen receptor T-cell (CAR-T) therapy. METHODS We conducted a double-blind, three-round modified Delphi panel among U.S.-based hematologist-oncologi...

R. Banerjee, Hamza Hashmi, Preety Chaudhary et al. · 0 citations
Review Open access Oct 2026

T-cell-redirecting therapies in early relapsed multiple myeloma: a systematic review and network meta-analysis

Chimeric antigen receptor T cells and bispecific antibodies, are moving from late-line salvage into early relapsed multiple myeloma. Indirect comparisons in heavily pretreated patients have favored cell therapy, but whether that hierarchy holds in early relapse is unknown. We analyzed randomized phase 3 trials comparin...

Maximilian Merz, J. Souto, P. Voorhees et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.